| Literature DB >> 34141085 |
Donghui Qin1, Xiaojuan Lin2, Zhi Liu2, Yan Chen2, Zhiliu Zhang2, Chengde Wu2, Linlin Liu2, Yan Pan2, Sylvie Laquerre1, John Emery1, Jeff Fergusson1, Kimberly Roland1, Rick Keenan1, Allen Oliff1, Sanjay Kumar1, Mui Cheung1, Dai-Shi Su1.
Abstract
We report herein the discovery of quinazolindiones as potent and selective tankyrase inhibitors. Elucidation of the structure-activity relationship of the lead compound 1g led to truncated analogues that have good potency in cells, pharmacokinetic (PK) properties, and excellent selectivity. Compound 21 exhibited excellent potencies in cells and proliferation studies, good selectivity, in vitro activities, and an excellent PK profile. Compound 21 also inhibited H292 xenograft tumor growth in nude mice. The synthesis, biological, pharmacokinetic, in vivo efficacy studies, and safety profiles of compounds are presented.Entities:
Year: 2021 PMID: 34141085 PMCID: PMC8201761 DOI: 10.1021/acsmedchemlett.1c00160
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.632